Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in NovemberBedrijfsupdate27 okt 2026ENPharming Group N.V.Company newsroom
Pharming Group announces third quarter 2026 revenues above market expectationsBedrijfsupdate22 okt 2026ENPharming Group N.V.Company newsroom
Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026Bedrijfsupdate14 okt 2026ENPharming Group N.V.Company newsroom
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSBedrijfsupdate25 sep 2026ENPharming Group N.V.Company newsroom
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026Bedrijfsupdate22 sep 2026ENPharming Group N.V.Company newsroom
FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.Bedrijfsupdate11 sep 2026ENPharming Group N.V.Company newsroom
Pharming Group to participate in September investor conferencesBedrijfsupdate9 sep 2026ENPharming Group N.V.Company newsroom
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderBedrijfsupdate13 aug 2026ENPharming Group N.V.Company newsroom
Pharming Group to participate in Canaccord Genuity 46th Annual Growth ConferenceBedrijfsupdate4 aug 2026ENPharming Group N.V.Company newsroom
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic useBedrijfsupdate30 jul 2026ENPharming Group N.V.Company newsroom
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30Bedrijfsupdate16 jul 2026ENPharming Group N.V.Company newsroom
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSBedrijfsupdate4 jun 2026ENPharming Group N.V.Company newsroom
Pharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkBedrijfsupdate2 jun 2026ENPharming Group N.V.Company newsroom
Pharming Group announces results of 2026 Annual General Meeting of ShareholdersBedrijfsupdate28 mei 2026ENPharming Group N.V.Company newsroom
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionBedrijfsupdate22 mei 2026ENPharming Group N.V.Company newsroom
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026Bedrijfsupdate7 mei 2026ENPharming Group N.V.Company newsroom
Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersBedrijfsupdate7 mei 2026ENPharming Group N.V.Company newsroom
Pharming Group to report first quarter 2026 financial results and provide business update on May 7Bedrijfsupdate23 apr 2026ENPharming Group N.V.Company newsroom
Pharming Group announces the 2026 Annual General Meeting of ShareholdersBedrijfsupdate16 apr 2026ENPharming Group N.V.Company newsroom
